Abstract
Ion channels have a critical role in cell proliferation and it is well documented that channel blockers can inhibit the growth of cancer cells. The concept of ion channels as therapeutic targets or prognostic biomarkers attracts increasing interest, but the lack of potent and selective channel modulators has hampered a critical verification for many years. Today, the knowledge of human ion channel genes is almost complete and molecular correlates for many native currents have already been identified. This information triggered a wave of experimental results, identifying individual ion channels with relevance for specific cancer types. The current pattern of cancer-related ion channels is not arbitrary, but can be reduced to few members from each ion channel family. This review aims to provide an overview of the molecularly identified ion channels that might be relevant for the most common human cancer types. Possible applications of these candidates for a targeted cancer therapy or for clinical diagnosis are discussed.
Similar content being viewed by others
References
Abdel-Ghany M., Cheng H.C., Elble R.C., Pauli B.U. 2001. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J. Biol. Chem. 276:25438–25446
Abdul M., Hoosein N. 2002a. Voltage-gated potassium ion channels in colon cancer. Oncol Rep 9:961–964
Abdul M., Hoosein N. 2002b. Expression and activity of potassium ion channels in human prostate cancer. Cancer. Lett. 186:99–105
Abdul M., Santo A., Hoosein N. 2003. Activity of potassium channel-blockers in breast cancer. Anticancer Res. 23:3347–3351
Bertz, J. Hentschel, S., Hundsdörfer, G., Kaatsch, P., Katalinic, A., Lehnert, M., Schön, D., Stegmair, C., Ziegler, H. 2004. Krebs in Deutschland. 4th revised Ed. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Saarbrücken
Braun S., Naume B. 2005. Circulating and disseminated tumor cells. J. Clin. Oncol. 23:1623–1626
Bustin S.A., Li S.R., Dorudi S. 2001. Expression of the Ca2+-activated chloride channel genes CLCA1 and CLCA2 is downregulated in human colorectal cancer. DNA Cell Biol. 20:331–338
Catterall. 2000. Structure and regulation of voltage-gated Ca2+ channels. Annu. Rev. Cell. Dev. Biol. 16:521–555
Chandy G.K., Wulff H., Beeton C., Pennington M., Gutman G.A., Cahalan M.D. 2004. K+ channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25:280–289
Chapman C.G., Meadows H.J., Godden R.J., Campbell D.A., Duckworth M., Kelsell R.E., Murdock P.R., Randall A.D., Rennie G.I., Gloger I.S. 2000. Cloning, localisation and functional expression of a novel human, cerebellum specific, two pore domain potassium channel. Brain Res. Mol. Brain Res. 82:74–83
Clapham D.E., Montell C., Schultz G., Julis D. 2003. International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: transient receptor potential channels. Pharmacol. Rev. 55:591–596
Debes J.D., Roberts R.O., Jacobson D.J., Girman C.J., Lieber M.M., Tindall D.J., Jacobson S.J. 2004. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol. Biomarkers Prev. 13:255–259
De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. 2002. Safety of non-antiarrhythmogenic drugs that prolong the QT interval or induce Torsade de pointes: an overview. Drug Saf. 25:263–286
Diss J.K., Archer S.N., Hirano J., Fraser S.P., Damgoz M.B. 2001. Expression profiles of voltage-gated Na+ channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate. 48:165–178
Doering C.J., Zamponi G.W. 2003. Molecular pharmacology of high voltage-activated calcium channels. J Bioenerg Biomembr 35:491–505
Duncan L.M., Deeds J., Cronin F.E., Donovan M., Sober A.J., Kauffman M., McCarthy J.J. 2001. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568–576
Duncan L.M., Deeds J., Hunter J., Shao J., Holmgren L.M., Woolf E.A., Tepper R.I., Shyan A.W. 1998. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 58:1515–1520
Elble, R.C., Pauli, B.U. 2001. Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium. J. Biol. Chem. 276:40510–40517
Farias L.M., Ocana D.B., Diaz L., Larrea F., Avila-Chavez E., Cadena A., Hinojosa L.M., Lara G., Villanueva L.A., Vargas C., Hernandez-Gallegos E., Camacho-Arroyo I., Duenas-Gonzalez A., Perez-Gardenas E., Pardo L.A., Morales A., Taja-Chayeb L., Escamilla J., Sanchez-Pena C., Camacho J. 2004. Ether a go-go potassium channels as human cervical cancer markers. Cancer Res. 64:6996–7001
Fixemer T., Wissenbach U., Flockerzi V., Bonkhoff H. 2003. Expression of Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 22:7858–7861
Fraser S.P., Salvador V., Manning E.A., Mizal J., Altun S., Raza M., Berridge R.J., Djamgoz M.B. 2003. Contribution of voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. J. Cell. Physiol. 195:479–487
Gavrilova-Ruch O., Schönherr K., Gessner G., Schönherr R., Klapperstück T., Wohlrab W., Heinemann S.H. 2002. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J. Membrane. Biol. 188:137–149
Gruber A.D., Pauli B.U. 1999. Tumorigenicity of human breast cancer is associated with loss of the Ca2+− activated chloride channel CLCA2. Cancer Res. 59:5488–5491
Gudermann T., Flockerzi V. 2005. TRP channels as new pharmacological targets. Naunyn-Schmiedeberg’s Arch. Pharmacol. 371:241–244
Henshall S.M., Afar D.E.H., Miller J., Horvarth L.G., Quinn D.I., Rasia. K.K., Gish K., Willhite D., Kench J.G., Gardiner-Garden M., Stricker P.D., Scher H.I., Grygiel J.J., Agus D.B., Mack D.H., Sutherland R.L. 2003. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196–4203
Izquierdo M. 2004. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12:217–27
Jäger, H., Dreker, T., Buck, A., Giehl, K., Gress, T., Grissmer, S. 2004. Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Mol. Pharmacol. 65:630–638
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., Thun, M.J. 2005. Cancer statistics 2005. CA Cancer J. Clin. 55:10–30
Kim C.J., Cho Y.G., Jeong S.W., Kim Y.S., Kim S.Y., Nam S.W., Lee S.H., Yoo N.J., Lee J.Y., Park W.S. 2004. Altered expression of KCNK9 in colorectal cancers. APMIS 112:588–594
Lanaido M.E., Lalani E.N., Fraser S.P., Grimes J.A., Bhangal G., Djamgoz M.B., Abel P.D. 1997. Expression and functional analysis of voltage-activated Na+ channels inhuman prostate cancer cell lines and their contribution to invasion in vitro. Am. J. Pathol. 150:1213–1221
Lastraioli E., Guasti L., Crociani O., PolvaniS., Hofmann G., Witchel H., Bencini L., Calistri M., Messerini L., Scatizzi M., Moretti R., Wanke E., Olivotto M., Mugnai G., Arcangeli A. 2004. herg1 Gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 64:606–611
Loberg R.D., Fridman Y., Pienta B.A., Keller E.T., McCauley L.K., Taichman R.S., Pienta K.J. 2004. Detection and isolation of circulating tumor cells in urologic cancers: A review. Neoplasia 6:302–309
Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Mariot P., Vanoverberghe K., Lalevee N., Rossier M.F., Prevarskaya N. 2002. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem 277:10824–10833
Meyer R. & Heinemann S.H. 1998. Characterization of an eag-like potassium channel in human neuroblastoma cells. J. Physiol. 508:49–56
Meyer R., Schönherr R., Gavrilova-Ruch O., Wohlrab W., Heinemann S.H. 1999. Identification of ether à go-go and calcium-activated potassium channels in human melanoma cells. J Membrane. Biol. 171:107–115
Monen S.H., Schmidt P.H., Wondergem R. 1998. Membrane potassium channels and human bladder tumor cells: I. Electrical properties. J. Membrane. Biol. 161:247–256
Mu D., Chen L.Y., Zhang X.P., See L.H., Koch C.M., Yen C., Tond J.J., Spiegel L, Nguyen K.C.Q., Servoss A., Peng Y., Pei L., Marks J.R., Lowe S., Hoey T., Jan L.Y., McCombie W.R., Wigler M.H., Powers S. 2003. Genomic amplification and oncogenic properties of the KCNP9 potassium channel gene Cancer Cell 3:297–302
Nilius B., Droogmans G. 2003. Amazing chloride channels: an overview. Acta Physiol. Scand. 177:119–147
Nilius B., Wohlrab W. 1992. Potassium channels and regulation of proliferation of human melanoma cells. J. Physiol. 445:537–548
Olsen M.L., Schade S., Lyons S.A., Amaral M.D., Sontheimer H. 2003. Expression of voltage-gated chloride channels in human glioma. cells. J. Neurosci. 23:5572–5582
Ouadid-Ahidouch H., Le Bourhis X., Roudbaraki M., Toillon R.A., Delcourt P., Prevarskaya N.H. 2001. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether a go-go K+ channel. Receptors Channels. 7:345–356
Ouadid-Ahidouch H., Roudbaraki M., Ahidouch A., Delcourt P., Prevarskaya N. 2004a. Cell-cycle-dependent expression of the large Ca2+-activated K+ channels in breast cancer cells. Biochem. Biophys. Res. Comm. 316:244–251
Ouadid-Ahidouch H., Roudbaraki M., Delcourt P., Ahidouch A., Loury N., Prevarskaya N. 2004b. Functional and molecular identification of intermediate-conductance Ca2+-activated K+ channels in breast cancer cells: association with cell cycle progression. Am. J. Physiol. 287:C125–C134
Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindemann N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Pardo L.A., del Camino D., Sánchez A., Alves F., Brüggemann A., Beckh S., Stühmer W. 1999. Oncogenic potential of EAG K+ channels. EMBO J. 18:5540–5547
Patel A.J., Lazdunski M. 2004. The 2P-domain K+ channels: role in apoptosis and tumorigenesis. Pfluegers Arch. - Eur. J. Physiol. 448:261–273
Patt, S., Preussat, K., Beetz, C., Kraft, R., Schrey, M., Kalff, R., Schönherr, K., Heinemann, S.H. 2004. Expression of ether a go-go potassium channels in human gliomas. Neurosci. Lett. 368:249–253
Peng, J.B., Zhuang, L, Berger, U.V., Adam, R.M., Williams, B.J., Brown, E.M., Hediger, M.A., Freeman, M.R. 2001. CaT1 expression correlates with tumor grade in prostate cancer. Biochem. Biophys. Res. Commun. 282:729–734
Rajan S., Wischmeyer E., Liu G.X., Preissig-Müller R., Daut J., Karschin A., Derst C. 2000. TASK-3, a novel tandem pore-domain acid-sensitive K+ channel: an intracellular histidine as pH sensor. J. Biol. Chem. 275:16650–16657
Rane, S.G. 2000. The growth regulatory fibroblast IK channel is the prominent electrophysiological feature of rat prostatic cancer cells. Biochem. Biophys. Res. Commun. 269:457–463
Ransom C.B., O’Neal J.T., Sontheimer H. 2001. Volume-activated chloride currents contribute to the resting conductance and invasive migration of human glioma cells. J. Neurosci. 21:7674–7683
Rouzaire-Dubois B., Milandri J.B., Bostel S., Dubois J.M. 2000. Control of cell proliferation by cell volume alterations in rat C6 glioma cells. Pfluegers Arch. 440:881–888
Rybalchenko V., Prevarskaya N., Van Coppenolle F., Legrand G., Lemonnier L, Le Bourhis X., Skryma R. 2001. Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Mol. Pharmacol. 59:1376–1387
Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. 1995. A mechanistic link between an inherited and an aquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299–307
Schoenherr K.M., Tajima N., Kaatz M., Heinemann S.H., Schoenherr R. 2005. Potassium channels in melanoma cells are functionally upregulated by chronic hypoxia. Proc. Amer. Assoc. Cancer Res. 46:[5234]
Schwab A., Reinhardt J., Schneider S.W., Gassner B., Schuricht B. 1999. K (+) channel-dependent migration of fibroblasts and human melanoma cells. Cell. Physiol. Biochem. 9:126–132
Shao, X.D., Wu, K.C., Hao, Z.M., Zhang, J., Fan, D.M. 2002. The potent inhibitory effects of cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells. Cancer Biol. Ther. 4:
Smith G.A.M., Tsui H.-W., Newell E.W., Jiang X., Zhu X.-P., Tsui F.W.L, Schlichter L.C. 2002. Functional up-regulation of HERG K+ channels in neoplastic hematopietic cells. J. Biol. Chem. 277:18528–18534
Stocker J.W., De Franceschi L., McNaughton-Smith G.A., Corrocher R., Beuzard Y., Brugnara C. 2003. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 101:2412–2418
Takanami I., Inoue Y., Gika M. 2004. G-protein inwardly rectifying potassium channel I (GIRK I) gene expression correlates with tumor progression in non-small cell lung cancer. BMC Cancer 4:79
Tong A.W., Zhang Y.-A., Nemunaitis J. 2005. Small interfering RNA for experimental cancer therapy. Curr. Op. Mol. Ther. 7:114–124
Tsavaler L., Shapero M.H., Morkowski S, Laus R. 2001. Trp-p8, a novel prostate-specific gene, is upregulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 61:3760–3769
Wang X.T., Nagaba Y., Cross H.S., Wrba F., Zhang L., Guggino S.E. 2000. The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am. J. Pathol. 157:1549–1562
Wickenden A.D. 2002. K+ channels as therapeutic drug targets. Pharmacology Therapeutics. 94:157–182
Wondergem R., Cregan M., Strickler L., Miller R., Suttles J. 1998. Membrane potassium channels and human bladder tumor cells: II. Growth properties. J. Membrane. Biol. 161:257–262
Wonderlin W.F., Strobl J.S. 1996. Potassium channels, proliferation and G1 progression. J. Membr. Biol. 154:91–107
Wulff H., Miller M.J., Hansel W., Grissmer S., Cahalan M.D., Chandy K.G. 2000. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCal: a potential immunosuppressant. Proc. Natl. Acad. Sci. USA. 97:8151–8156
Xu X.Z., Moebius F., Gill D.L., Montell C. 2001. Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform. Proc. Natl. Acad. Sci. USA 98:10692–10697
Acknowledgement
This work was supported by IZKF Jena (TMWFK B307-04004). I thank S.H. Heinemann for his constant support of my work, K. Schönherr for helpful discussions and A. Hansel and G. Albrecht for critically reading this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schönherr, R. Clinical Relevance of Ion Channels for Diagnosis and Therapy of Cancer. J Membrane Biol 205, 175–184 (2005). https://doi.org/10.1007/s00232-005-0782-3
Received:
Issue Date:
DOI: https://doi.org/10.1007/s00232-005-0782-3